Disease relevance of Efrotomycin

• In contrast, extracts from B. subtilis failed to restore activity in an efrotomycin-inhibited E. coli system [1].
• A total of 107 Enterococcus strains, 10 Vagococcus fluvialis strains, and 8 Lactococcus garvieae strains were tested for acidification of methyl-alpha-D-glucopyranoside (MGP) and susceptibility to 100-microg efrotomycin (EFRO) disks [2].
• The susceptibility of 69 clinical isolates of Clostridium difficile from the Minneapolis Veterans Administration Medical Center and 29 C. difficile strains from other hospitals to efrotomycin, ciprofloxacin, and six other antimicrobials was tested in vitro by agar dilution [3].
• The antibiotic efrotomycin (I), C59H88N2O20, was isolated from cultures of Nocardia lactamdurans as an amorphous yellow powder [4].
• The influence of efrotomycin administered at the rate of 16 mg/kg of feed in 10 Salmonella typhimurium-inoculated pigs was determined by comparing this group with a group of 10 pigs inoculated with S typhimurium that were given nonmedicated feed [5].

High impact information on Efrotomycin

• Homologous and heterologous reconstituted systems were used to compare the effects of MDL 62,879 and of efrotomycin, an EF-Tu inhibitor of the kirromycin class, which is inactive against both B. subtilis and E. coli [1].
• Dominance or resistance to MDL 62,879 and of sensitivity to efrotomycin in heterologous cell-free protein synthesis confirms that inhibition of EF-Tu by the two antibiotics is mediated by different mechanisms of action [1].
• Six studies involving 700 pigs were conducted in five separate swine research facilities to evaluate weight gain and efficiency of feed utilization in pigs fed the antibiotic efrotomycin [6].
• Heneicomycin compared favorably with efrotomycin when given subcutaneously or per os against infections with Moraxella bovis and Streptococcus pyogenes [7].
• EF-Tus from streptococci were significantly less sensitive than EF-Tus from Gram-negative bacteria to both efrotomycin and pulvomycin [8].

Biological context of Efrotomycin

• Although efrotomycin is unrelated to any antibacterial drug used in human or veterinary medicine, the possibility of cross-resistance with other antibacterials is of concern [9].
• Subinhibitory concentrations of efrotomycin had no effect on the conjugative transfer of antibacterial-resistance plasmids between K-12 strains of Escherichia coli [9].

Associations of Efrotomycin with other chemical compounds

• Sensitivity of elongation factor Tu (EF-Tu) from different bacterial species to the antibiotics efrotomycin, pulvomycin and MDL 62879 [8].

Gene context of Efrotomycin

• Inhibition of bacterial protein synthesis by elongation-factor-Tu-binding antibiotics MDL 62,879 and efrotomycin [1].
• Among Gram-positive bacteria, EF-Tu of Bacillus subtilis, Staphylococcus aureus and Enterococcus faecalis was resistant to efrotomycin and less sensitive to pulvomycin than EF-Tu of Gram-negative bacteria [8].

Analytical, diagnostic and therapeutic context of Efrotomycin

• Determination of efrotomycin in feeds by high-performance liquid chromatography [10].
• Two control groups of 4 noninoculated pigs each, 1 group medicated with efrotomycin at 16 mg/kg of feed, the other nonmedicated, also were evaluated [5].
• The raid elimination of heneicomycin observed following oral administration may account for its poor activity against a Bordetella bronchiseptica infection where efrotomycin is effective [7].
• The minimum inhibitory concentrations (MICs) of efrotomycin were determined for a broad panel of bacterial isolates [9].
• When the MIC of efrotomycin for nine selected isolates was increased from 16- to greater than 100-fold by serial passage in subinhibitory concentrations of efrotomycin, no increased resistance to the 15 antibacterials was noted [9].

References